In search of physiologically based distribution volume estimates for macromolecules

Area of Science:

• Pharmacokinetics and pharmacodynamics
• Biopharmaceutical modeling
• Oncology drug development

Background:

• Trastuzumab emtansine (T-DM1) is an antibody-drug conjugate used in cancer therapy.
• Accurate pharmacokinetic (PK) modeling is crucial for optimizing T-DM1 efficacy and safety.
• Previous PK analyses of T-DM1 and similar macromolecules have employed distribution models.

Purpose of the Study:

• To evaluate the pharmacokinetic modeling approach used for trastuzumab emtansine (T-DM1).
• To assess the physiological plausibility of the distribution models applied to T-DM1 pharmacokinetics.
• To highlight the limitations of statistical versus physiological considerations in macromolecule PK modeling.

Main Methods:

• Semimechanistic analysis of T-DM1 pharmacokinetics.
• Modeling T-DM1 deconjugation using transit compartments for plasma volume.
• Employing a single peripheral compartment in the distribution model.

Main Results:

• The study identified the two-compartment distribution model used for T-DM1 as physiologically implausible.
• This modeling approach, guided by statistical rather than physiological factors, may misrepresent T-DM1 distribution kinetics.
• Similar limitations were noted in other recent analyses of trastuzumab and macromolecule distribution.

Conclusions:

• The current pharmacokinetic modeling strategies for T-DM1 require re-evaluation.
• Physiologically informed modeling is essential for a more accurate understanding of T-DM1 distribution and behavior.
• Future research should prioritize biologically realistic models for antibody-drug conjugates.